Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Copyright 2025 The Associated Press. All Rights Reserved. A local resident receives the Moderna COVID-19 vaccine shot at a ...

Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.